Ask AI
Back Back
ADA 2026 obesity studies

CE / CME

Translating Emerging Obesity Evidence Into Clinical Action: Highlights From ADA 2026

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: July 21, 2026

Expiration: July 20, 2027

Donna H. Ryan
Donna H. Ryan, MD
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Obesity Themes at ADA 2026

In this module, I will review the major obesity themes and implications that emerged from ADA 2026, which was held in New Orleans from June 5 to 8.

The first is the phase III TRIUMPH-1 trial of retatrutide, which was 1 of the most highly anticipated studies presented this year. I will also discuss 2 post hoc analyses on the ATTAIN-1 and OASIS 4 trials, evaluating oral orforglipron and semaglutide, respectively. The last is a mechanistic study of CagriSema—a fixed-dose combination of cagrilintide and semaglutide—that looked to better understand its mechanism of action.

Before getting into the details, several overarching themes emerged across these 4 studies. The first considers the anticipated magnitude of weight loss, with increasingly robust and durable reductions in total body weight reported. Another important theme is metabolic risk, including treatment effects on glycemia, insulin sensitivity, and other cardiometabolic outcomes. Then there are route of administration and treatment fit, as both oral and injectable therapies expand the obesity treatment landscape. Finally, these studies reinforce the importance of biology, particularly the role of appetite regulation, reward pathways, and the mechanisms underlying food intake, in understanding obesity as a chronic disease.

Perhaps the most important clinical insight from ADA 2026 is that BMI should only serve as an entry point in obesity management. It should not be the sole determinant of treatment selection. Therefore, clinical decision-making should be individualized according to patients' weight trajectory, comorbidities, prior weight loss efforts and treatment response, tolerability, access to therapy, and preferences.1-4

Download

Before You Change Your Practice: 4 Questions to Ask Yourself

It is generally understood in medicine that it takes years for new therapies and emerging evidence to finally be incorporated into the obesity guidelines. That means the findings presented at ADA 2026 are not yet ready for implementation into obesity care pathways, but healthcare professionals (HCPs) should be watching these studies closely. Some outcomes can be incorporated into our own conceptual framework of obesity, while others may be practice changing and adopted accordingly.

When it comes to interpreting new evidence, HCPs must be careful and selective. We should all know how to evaluate the evidence by looking at the study phase, randomization, treatment duration, and comparator (ie, placebo vs active control). The strength of the evidence is important when interpreting new data.

Are the results meaningful? There is a difference between clinical and statistical superiority. Are the outcomes clinically meaningful or simply statistically significant? This requires HCPs to consider the benefit size, thresholds, and patient centeredness of the study.

Is it practical? Safety is always an important consideration, as is dose titration, monitoring, and patients’ ability to access care and treatment. If patients cannot afford their medicine, then they cannot access it. This is why it is critical that HCPs consider and address practicality when providing comprehensive obesity care.

Finally, what is the action level? Should we just put the new evidence away in our memory banks and wait for more data? Are we going to use the evidence today? How should we discuss this with patients and help them choose their treatment?

The take-home message is simple: ADA 2026 findings should inform your clinical judgement, not automatically change established care pathways.

Download
BACK | NEXT